Gathering the record
Relay is organizing the evidence and source boundaries.
GLP-1 receptor agonist
Semaglutide is a GLP-1 receptor agonist available in several FDA-approved injections and tablets. The evidence base spans weight management, type 2 diabetes, cardiovascular outcomes, chronic kidney disease, and a defined MASH population—but the brands and formulations are not interchangeable.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Semaglutide is a medicine that mimics one natural hormone signal involved in appetite, digestion, and blood-sugar regulation. Several injection and tablet products are approved.
Its unusually broad human record allows researchers to examine weight, diabetes, cardiovascular disease, kidney disease, and a defined liver-disease population. That breadth also helps researchers ask how one pathway affects several related diseases.
Large controlled trials have demonstrated benefits for specific weight, blood-sugar, cardiovascular, kidney, and liver outcomes. Each finding belongs to the product, route, population, and outcome actually studied.
Long-term comparisons with newer medicines, uncommon harms, and results outside labeled populations remain incomplete. Injection and oral products are not interchangeable, and approved products do not validate independent powder vials.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Current FDA labeling separates WEGOVY injection from oral semaglutide and describes administration only for the named product and indication.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Large trials and approved products cover injectable and oral formulations across several metabolic outcomes.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Weight, cardiovascular, kidney, diabetes, pediatric-obesity, and MASH findings are supported by large controlled programs in defined populations.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Injection and oral semaglutide are separate product records and are not interchangeable. The label does not validate compounded or research-vial concentration, reconstitution, handling, or stability. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple large randomized Phase 3 trials and outcomes trials support defined weight, cardiovascular, kidney, diabetes, pediatric-obesity, and MASH findings. SELECT enrolled 17,604 participants, and FLOW enrolled 3,533.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term comparative outcomes across newer formulations and doses, rare-event characterization at population scale, and whether trial results extend to unstudied populations or unapproved products.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
It activates the GLP-1 receptor. Mechanism helps explain biological effects, while clinical benefits and risks come from product-specific human trials and labels.
Large placebo-controlled trials include adults, adolescents, and a newer higher-dose adult program.
Current U.S. labels cover distinct uses across Wegovy injections and tablets, Wegovy HD, Ozempic injections and tablets, and Rybelsus.
Major cardiovascular events occurred in 6.5% with semaglutide and 8.0% with placebo over a mean 39.8 months of follow-up.
The primary kidney-and-cardiovascular composite was lower with semaglutide than placebo in the studied population.
At 72 weeks, both MASH resolution and fibrosis-improvement outcomes favored semaglutide in adults with noncirrhotic MASH and F2-F3 fibrosis.
SURMOUNT-5 reported -20.2% mean weight change with tirzepatide and -13.7% with semaglutide at 72 weeks.
Nausea, vomiting, diarrhea, constipation, and abdominal symptoms are common. Labels also address thyroid C-cell-tumor risk in rodents, MTC/MEN2 contraindications, pancreatitis, gallbladder disease, volume depletion, severe gastrointestinal reactions, retinopathy, hypoglycemia with some diabetes medicines, hypersensitivity, and aspiration risk.
Current labels describe prefilled injection presentations and tablets, each with product-specific storage and administration rules.
Mechanisms
Semaglutide is a long-acting GLP-1 analog with GLP-1-receptor agonist activity. Its product-specific evidence base includes large randomized trials in adults and adolescents with obesity, type 2 diabetes, established cardiovascular disease, chronic kidney disease, and noncirrhotic MASH with F2-F3 fibrosis. Current U.S. products include weekly subcutaneous and daily oral presentations with distinct indications, strengths, administration rules, and storage instructions.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled and active-controlled trial
Adults with obesity and without diabetes
Mean weight change was -18.7% with 7.2 mg, -15.6% with 2.4 mg, and -3.9% with placebo. Gastrointestinal events and altered skin sensation were more common at 7.2 mg.
Study administration: Once-weekly subcutaneous semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo
Limitations: The result is tied to the STEP UP population, protocol, estimand, and Wegovy HD program; it should not be generalized to other semaglutide products.
Open-label, randomized, active-controlled trial
Adults with obesity, without diabetes, and at least one obesity-related complication
Mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide; mean waist change was -18.4 cm and -13.0 cm.
Study administration: Maximum tolerated once-weekly tirzepatide 10 or 15 mg versus semaglutide 1.7 or 2.4 mg
Limitations: This was one sponsor-funded, open-label obesity trial. It did not test semaglutide 7.2 mg and does not compare cardiovascular, kidney, diabetes, MASH, or other outcomes.
Ongoing multicenter, randomized, double-blind, placebo-controlled trial
Adults with biopsy-defined MASH and stage F2 or F3 liver fibrosis
MASH resolution without worsening fibrosis occurred in 62.9% versus 34.3%; fibrosis improvement without worsening MASH occurred in 36.8% versus 22.4%.
Study administration: Once-weekly subcutaneous semaglutide 2.4 mg or placebo
Limitations: These are planned interim histology results from the first 800 participants. The trial and confirmatory clinical-outcome follow-up are ongoing.
International, randomized, double-blind, placebo-controlled, event-driven trial
Adults with type 2 diabetes and chronic kidney disease
The primary kidney-and-cardiovascular composite occurred less often with semaglutide than placebo (hazard ratio 0.76).
Study administration: Once-weekly subcutaneous semaglutide 1 mg or placebo
Limitations: This was a defined type 2 diabetes plus chronic-kidney-disease population using a specific approved formulation and dose.
International, randomized, double-blind, placebo-controlled, event-driven superiority trial
Adults age 45 or older with established cardiovascular disease and overweight or obesity, without diabetes
A major cardiovascular event occurred in 6.5% with semaglutide and 8.0% with placebo (hazard ratio 0.80). Discontinuation from adverse events was more frequent with semaglutide.
Study administration: Once-weekly subcutaneous semaglutide 2.4 mg or placebo
Limitations: The result applies to people with preexisting cardiovascular disease and overweight or obesity without diabetes; it is not a general prevention result for everyone.
Randomized, double-blind, placebo-controlled trial
Adolescents age 12 to under 18 with obesity, or overweight plus a weight-related condition
Mean BMI change at week 68 was -16.1% with semaglutide and +0.6% with placebo; 73% versus 18% reached at least 5% weight reduction.
Study administration: Once-weekly subcutaneous semaglutide 2.4 mg or placebo, with lifestyle intervention
Limitations: This was a 201-participant adolescent trial; it does not establish outcomes in younger children or every pediatric population.
Randomized, double-blind, placebo-controlled trial
Adults with obesity, or overweight plus a weight-related condition, without diabetes
Mean weight change at week 68 was -14.9% with semaglutide and -2.4% with placebo; 86.4% versus 31.5% reached at least 5% weight reduction.
Study administration: Once-weekly subcutaneous semaglutide 2.4 mg or placebo, with lifestyle intervention
Limitations: The trial excluded diabetes and used protocol-defined escalation plus lifestyle support. Group averages do not predict an individual result.
Double-blind, parallel-group, placebo-controlled trial
Adults with obesity
Ad-libitum energy intake was 35% lower with semaglutide, with lower hunger and higher fullness and satiety than placebo at week 20.
Study administration: Once-weekly subcutaneous semaglutide escalated to 2.4 mg or placebo
Limitations: This was a small, short pharmacology study using proxy and self-reported outcomes; it does not predict an individual appetite response.
Safety snapshot
Gastrointestinal adverse effects are common, and current labels contain important contraindications and warnings.
Controlled human evidenceRisk varies by product, population, dose, duration, other medicines, and health history. This summary does not replace the current label.
Open sourceGastrointestinal adverse effects are common, and current labels contain important contraindications and warnings.
Controlled human evidenceThe stated frequency is source-, product-, population-, route-, dose-, comparator-, and duration-specific; it is not a universal incidence estimate.
Open sourceGastrointestinal adverse effects are common, and current labels contain important contraindications and warnings.
Controlled human evidenceRisk varies by product, population, dose, duration, other medicines, and health history. This summary does not replace the current label.
Open sourceA major cardiovascular event occurred in 6.5% with semaglutide and 8.0% with placebo (hazard ratio 0.80). Discontinuation from adverse events was more frequent with semaglutide.
Controlled human evidenceStudy discontinuation describes what happened under a study protocol; it is not an emergency-action threshold.
Open sourceNo compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-18
2026-06-01
2026-01-30
2025-09-14 · PMID 40961952 · NCT05646706 · DOI 10.1016/S2213-8587(25)00226-8
2025-05-11 · PMID 40353578 · NCT05822830 · DOI 10.1056/NEJMoa2416394
2025-04-30 · PMID 40305708 · NCT04822181 · DOI 10.1056/NEJMoa2413258
2024-05-24 · PMID 38785209 · NCT03819153 · DOI 10.1056/NEJMoa2403347
2023-11-11 · PMID 37952131 · NCT03574597 · DOI 10.1056/NEJMoa2307563
2022-11-02 · PMID 36322838 · NCT04102189 · DOI 10.1056/NEJMoa2208601
2021-02-10 · PMID 33567185 · NCT03548935 · DOI 10.1056/NEJMoa2032183
2021-01-03 · PMID 33269530 · NCT03767582 · DOI 10.1111/dom.14280